Integrating molecular interactions and gene expression to identify biomarkers to predict response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients.

<bold>Background: </bold>Targeted therapy using anti-TNF (tumor necrosis factor) is the first option for patients with rheumatoid arthritis (RA). Anti-TNF therapy, however, does not lead to meaningful clinical improvement in many RA patients. To predict which patients will not benefit from anti-TNF therapy, clinical tests should be performed prior to treatment beginning.<bold>Objective: </bold>Although various efforts have been made to identify biomarkers and pathways that may be helpful to predict the response to anti-TNF treatment, gaps remain in clinical use due to the low predictive power of the selected biomarkers.<bold>Methods: </bold>In this paper, we used a network-based computational method to identify the select the predictive biomarkers to guide the treatment of RA patients.<bold>Results: </bold>We select 69 genes from peripheral blood expression data from 46 subjects using a sparse network-based method. The result shows that the selected 69 genes might influence biological processes and molecular functions related to the treatment.<bold>Conclusions: </bold>Our approach advances the predictive power of anti-TNF therapy response and provides new genetic markers and pathways that may influence the treatment. [ABSTRACT FROM AUTHOR]